Mylan Announces Filing of Modafinil ANDA

PITTSBURGH--(BUSINESS WIRE)--April 2, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it received confirmation from the FDA in February, 2003 that the Company's Modafinil (Provigil®) ANDA has been accepted for filing.

The FDA accepted Mylan's application which contains a Paragraph IV certification, effective December 24, 2002, the earliest date on which FDA could accept an application for Cephalon's Provigil® 100 mg and 200 mg tablets. As a result, Mylan believes this to be a potential first to file opportunity for this product which has annual sales in excess of $200 million.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through its three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc., as well as branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. We refer you to the risk factors and other disclosures contained in our periodic SEC filings. We undertake no duty to update our forward-looking statements, even though our situation may change in the future.

CONTACT: Mylan Laboratories Inc. Kris King, 412-232-0100

SOURCE: Mylan Laboratories Inc.